[1] |
Izquierdo-Sanchez L, Lamarca A, La Casta A, et al. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry[J]. J Hepatol, 2022, 76(5):1109-1121.
|
[2] |
Krasinskas AM. Cholangiocarcinoma[J]. Surg Pathol Clin, 2018, 11(2):403-429.
|
[3] |
Bragazzi MC, Ridola L, Safarikia S, et al. New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin[J]. Ann Gastroenterol, 2018, 31(1):42-55.
|
[4] |
Zhang XF, Xue F, Dong DH, et al. Number and station of lymph node metastasis after curative-intent resection of intrahepatic cholangiocarcinoma impact prognosis[J]. Ann Surg, 2021, 274(6): e1187-1195.
|
[5] |
Kim SH, Han DH, Choi GH, et al. Prognostic impact of the metastatic lymph node number in intrahepatic cholangiocarcinoma[J]. Surgery, 2022, 172(1):177-183.
|
[6] |
Sposito C, Droz Dit Busset M, Virdis M, et al. The role of lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma: a review[J]. Eur J Surg Oncol, 2022, 48(1):150-159.
|
[7] |
科技部传染病防治重大专项课题"病毒性肝炎相关肝癌外科综合治疗的个体化和新策略研究"专家组. 肝内胆管癌外科治疗中国专家共识(2020版)[J]. 中华消化外科杂志, 2021, 20(1):1-15.
|
[8] |
Zhou R, Lu D, Li W, et al. Is lymph node dissection necessary for resectable intrahepatic cholangiocarcinoma? a systematic review and meta-analysis[J]. HPB, 2019, 21(7):784-792.
|
[9] |
陈亚进, 周睿. 可根治性切除肝内胆管细胞癌肝周围淋巴结清扫的探讨[J]. 中华消化外科杂志, 2019, 18(1):48-52.
|
[10] |
Miyata T, Yamashita YI, Yamao T, et al. Clinical benefits of lymph node dissection in intrahepatic cholangiocarcinoma: a retrospective single-institution study[J]. Anticancer Res, 2017, 37(5):2673-2677.
|
[11] |
Amini N, Ejaz A, Spolverato G, et al. Management of lymph nodes during resection of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a systematic review[J]. J Gastrointest Surg, 2014, 18(12):2136-2148.
|
[12] |
王垒, 林自国, 杨田, 等. 淋巴结清扫在肝内胆管癌根治术中临床价值的多中心回顾性研究[J]. 中华消化外科杂志, 2020, 19(1):72-80.
|
[13] |
Yoh T, Cauchy F, Le Roy B, et al. Prognostic value of lymphadenectomy for long-term outcomes in node-negative intrahepatic cholangiocarcinoma: a multicenter study[J]. Surgery, 2019, 166(6):975-982.
|
[14] |
Ke Q, Wang L, Lin Z, et al. Prognostic value of lymph node dissection for intrahepatic cholangiocarcinoma patients with clinically negative lymph node metastasis: a multi-center study from China[J]. Front Oncol, 2021(11):585808.
|
[15] |
Umeda Y, Mitsuhashi T, Kojima T, et al. Impact of lymph node dissection on clinical outcomes of intrahepatic cholangiocarcinoma: inverse probability of treatment weighting with survival analysis[J].J Hepatobiliary Pancreat Sci, 2022, 29(2):217-229.
|
[16] |
马伟虎, 雷正清, 余秋石, 等. 肝内胆管癌淋巴结转移个体化术前预测模型的构建及应用[J]. 中华外科杂志, 2022, 60(4):363-371.
|
[17] |
魏妙艳, 张园园, 耿智敏, 等. 肝内胆管癌临床病理特征及淋巴结转移特点的多中心回顾性研究(附1 321例报告)[J]. 中华消化外科杂志, 2018, 17(3):257-265.
|
[18] |
Mantovani A. Cancer: inflaming metastasis[J]. Nature, 2009, 457(7225):36-37.
|
[19] |
Zhang Y, Shi SM, Yang H, et al. Systemic inflammation score predicts survival in patients with intrahepatic cholangiocarcinoma undergoing curative resection[J]. J Cancer, 2019, 10(2):494-503.
|
[20] |
Huang J, Wang X, Zhu Y, et al. Specific prognostic factors in hepatitis B virus-related and non-hepatitis B virus-related intrahepatic cholangiocarcinoma after macroscopic curative resection[J]. J Surg Oncol, 2019, 119(1):40-46.
|
[21] |
徐原. 肝内胆管结石相关性肝内胆管细胞癌的临床病理特征及预后分析[J/CD]. 临床检验杂志(电子版), 2018, 7(4):588-589.
|
[22] |
Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019, 20(5):663-673.
|